The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1467
Umeclidinium (Incruse Ellipta) for COPD
The full article is available to subscribers Subscriber Login   

The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium was initially approved in combination with the long-acting beta2-adrenergic agonist vilanterol as Anoro Ellipta.1

MAINTENANCE TREATMENT — In patients with moderate to severe COPD, regular treatment with an inhaled long-acting bronchodilator (a beta2-agonist or an anticholinergic) can relieve symptoms, improve lung function, and reduce the frequency of exacerbations. A combination of a beta2-agonist and an anticholinergic can be used for patients inadequately controlled on a single agent.2

CLINICAL STUDIES — In a 12-week, double-blind trial, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Umeclidinium (Incruse Ellipta) for COPD
Article code: 1467c
 Electronic, downloadable article - $25